U.S. Food and Drug Administration officials are taking a second look at blood thinning drug Pradaxa ( dabigatran etexilate mesylate ) after reports of serious, potentially fatal, bleeding.

A drug that aids patients with intermittent atrial fibrillation, a common heart arrhythmia, increased the risk of death among patients with permanent atrial fibrillation. As a result the study was halted early.

An experimental drug designed to aid severely ill patients after hospitalization is not more effective than standard treatments for reducing the risk of blood clots, a study has confirmed.

U.S. Food and Drug Administration officials have given the green light to anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in patients with a common heart arrhythmia called atrial fibrillation.

For patients with atrial fibrillation, a common heart arrhythmia, the most serious risk is their heightened susceptibility to stroke. But half of patients are unaware of the risk or choose to ignore it.

In a what came as a surprise move to many, the U.S. Food and Drug Administration advisory committee today voted to recommend heart arrhythmia drug rivaroxiban (Xarelto) for approval.

U.S. Food and Drug Administration reviewers have warned against immediate approval of rivaroxaban (Xarelto) and questioned effectiveness of the medication for preventing stroke in high-risk atrial fibrillation patients.

Atrial fibrillation, a common heart arrhythmia, is generally treated with a standard drug warfarin. However, a study suggests a new drug might provide the same treatment, but with a lower risk of stroke and embolism.

According to a new report, an anti-clotting drug appears to be more effective at curbing stroke risk than aspirin in atrial fibrillation patients unable to take stronger drugs.

A meta-analysis of 14 studies has led researchers to believe that even moderate alcohol consumption can contribute to atrial fibrillation, or irregular heart beat.